Brean Capital Reiterates Upbeat View of Osiris Therapeutics Following 4Q Earnings
In a research report published Friday, Brean Capital analyst Difei Yang maintained a Buy rating on Osiris Therapeutics, Inc. (NASDAQ:OSIR) with a $19.00 price target, after the company released its fourth-quarter earnings results, with slight miss on EPS and a beat on revenue. Osiris shares are currently trading at $18.57, up $1.63 or 9.62 percent.
Yang noted, “Revenue was at $19.3 million vs. consensus of $18.9 million. EPS was $0.02, a slight miss from consensus of $0.05. We would like to point out a couple of things. We consider Q4 performance as meeting expectations. The miss on EPS by $0.03 is insignificant, especially for a company at a stage where profitability is still small; any small changes in operations could easily swing EPS results. In Osiris’ case, the company spent more on R&D in anticipation of the start of a confirmatory Phase III trial to support a BLA filing of Grafix. We believe looking at the company on a annual or bi-annual basis is more proper given the inherent volatility of quarterly results at the inflection point.”
Bottom line, “The company has a clean balance sheet and operations have reached the break-even point with a possibility to drive significantly positive EPS in the coming 12-24 months.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Difei Yang has a total average return of 10.9% and a 70.4% success rate. Yang has a 11.7% average return when recommending OSIR, and is ranked #900 out of 3505 analysts.